As of 2024-12-13, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 16.3x | 14.9x |
| Forward P/E multiples | 15.6x - 18.5x | 16.3x |
| Fair Price | (101.21) - (106.15) | (101.21) |
| Upside | -233.1% - -239.6% | -233.1% |
| Date | EV/EBITDA |